Advances in Research on Neuroendocrine Disorders Induced by Hyperandrogenism in Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20240683

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, with a high global prevalence. Its impact spans from puberty to menopause, characterized by hyperandrogenemia, ovulatory disorders, and polycystic ovary. Although the pathogenesis of PCOS is not yet fully understood, the central neuroendocrine system plays a significant role in the pathophysiology of PCOS indicated by many studies. One of the important mechanisms developing PCOS is below. High levels of androgens interfere with the activity of gonadotropin-releasing hormone (GnRH) neurons, and affect the feedback regulation of gonadal steroid hormones, leads to dysfunction of the hypothalamic-pituitary-gonadal (HPG) axis that regulates reproductive function in the central nervous system. This article reviewed how hyperandrogenemia induces neuroendocrine disorders in PCOS and explored the potential directions of future researches. It is hoped to provide a scientific basis for further revealing the pathogenesis of PCOS and developing new therapeutic approaches.

Key words: Polycystic ovary syndrome, Androgens, Neurosecretory systems, Gonadotropin-releasing hormone, Arcuate nucleus of hypothalamus

LI Chen-xi, FAN Meng-xiao, WU Lin-ling, DOU Zhen, JIA Jia, SUN Ya-xuan. Advances in Research on Neuroendocrine Disorders Induced by Hyperandrogenism in Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 698-702.

References 29

[1]	Wu Q, Gao J, Bai D, et al. The prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis[J]. Ann Palliat Med, 2021, 10(1):74-87. doi: 10.21037/apm-20-1893. pmid: 33545750
[2]	Stańczak NA, Grywalska E, Dudzińska E. The latest reports and treatment methods on polycystic ovary syndrome[J]. Ann Med, 2024, 56(1):2357737. doi: 10.1080/07853890.2024.2357737.
[3]	Singh S, Pal N, Shubham S, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics[J]. J Clin Med, 2023, 12(4):1454. doi: 10.3390/jcm12041454.
[4]	Glendining KA, Campbell RE. Recent advances in emerging PCOS therapies[J]. Curr Opin Pharmacol, 2023, 68:102345. doi: 10.1016/j.coph.2022.102345.
[5]	Ye W, Xie T, Song Y, et al. The role of androgen and its related signals in PCOS[J]. J Cell Mol Med, 2021, 25(4):1825-1837. doi: 10.1111/jcmm.16205. pmid: 33369146
[6]	Zuloaga DG, Lafrican JJ, Zuloaga KL. Androgen regulation of behavioral stress responses and the hypothalamic-pituitary-adrenal axis[J]. Horm Behav, 2024, 162:105528. doi: 10.1016/j.yhbeh.2024.105528.
[7]	Silva M, Campbell RE. Polycystic Ovary Syndrome and the Neuroendocrine Consequences of Androgen Excess[J]. Compr Physiol, 2022, 12(2):3347-3369. doi: 10.1002/cphy.c210025. pmid: 35578968
[8]	Moore AM, Lohr DB, Coolen LM, et al. Prenatal Androgen Exposure Alters KNDy Neurons and Their Afferent Network in a Model of Polycystic Ovarian Syndrome[J]. Endocrinology, 2021, 162(11):bqab158. doi: 10.1210/endocr/bqab158.
[9]	Xu G, Zhao X, Li Z, et al. Effects of electroacupuncture on the kisspeptin-gonadotropin-releasing hormone (GnRH) /luteinizing hormone (LH) neural circuit abnormalities and androgen receptor expression of kisspeptin/neurokinin B/dynorphin neurons in PCOS rats[J]. J Ovarian Res, 2023, 16(1):15. doi: 10.1186/s13048-022-01078-x. pmid: 36650561
[10]	Abbott DH. Neuronal androgen receptor: Molecular gateway to polycystic ovary syndrome?[J]. Proc Natl Acad Sci U S A, 2017, 114(16):4045-4047. doi: 10.1073/pnas.1703436114.
[11]	Garg A, Patel B, Abbara A, et al. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)[J]. Clin Endocrinol(Oxf), 2022, 97(2):156-164. doi: 10.1111/cen.14704.
[12]	Nagae M, Uenoyama Y, Okamoto S, et al. Direct evidence that KNDy neurons maintain gonadotropin pulses and folliculogenesis as the GnRH pulse generator[J]. Proc Natl Acad Sci U S A, 2021, 118(5):e2009156118. doi: 10.1073/pnas.2009156118.
[13]	Szeliga A, Rudnicka E, Maciejewska-Jeske M, et al. Neuroendocrine Determinants of Polycystic Ovary Syndrome[J]. Int J Environ Res Public Health, 2022, 19(5):3089. doi: 10.3390/ijerph19053089.
[14]	Markantes GK, Panagodimou E, Koika V, et al. Placental mRNA Expression of Neurokinin B Is Increased in PCOS Pregnancies with Female Offspring[J]. Biomedicines, 2024, 12(2):334. doi: 10.3390/biomedicines12020334.
[15]	Gurule S, Sustaita-Monroe J, Padmanabhan V, et al. Developmental programming of the neuroendocrine axis by steroid hormones: Insights from the sheep model of PCOS[J]. Front Endocrinol(Lausanne), 2023, 14:1096187. doi: 10.3389/fendo.2023.1096187.
[16]	McCarthy EA, Dischino D, Maguire C, et al. Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms[J]. J Clin Endocrinol Metab, 2022, 107(1):e328-e347. doi: 10.1210/clinem/dgab602.
[17]	王莹莹, 郑洲, 张秀明. 高浓度雄激素诱导KNDy神经内分泌紊乱在多囊卵巢综合征发病机制中的研究进展[J]. 国际妇产科学杂志, 2022, 49(5):497-501. doi: 10.12280/gjfckx.20220496.
[18]	Moore AM, Novak AG, Lehman MN. KNDy Neurons of the Hypothalamus and Their Role in GnRH Pulse Generation: an Update[J]. Endocrinology, 2023, 165(2):bqad194. doi: 10.1210/endocr/bqad194.
[19]	Moore AM. Impaired steroid hormone feedback in polycystic ovary syndrome: Evidence from preclinical models for abnormalities within central circuits controlling fertility[J]. Clin Endocrinol(Oxf), 2022, 97(2):199-207. doi: 10.1111/cen.14711.
[20]	Ye Z, Zhang C, Wang S, et al. Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances[J]. Reprod Biomed Online, 2022, 44(4):737-746. doi: 10.1016/j.rbmo.2021.11.012.
[21]	Walters KA, Gilchrist RB, Ledger WL, et al. New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins[J]. Trends Endocrinol Metab, 2018, 29(12):841-852. doi: 10.1016/j.tem.2018.08.005.
[22]	Porter DT, Moore AM, Cobern JA, et al. Prenatal Testosterone Exposure Alters GABAergic Synaptic Inputs to GnRH and KNDy Neurons in a Sheep Model of Polycystic Ovarian Syndrome[J]. Endocrinology, 2019, 160(11):2529-2542. doi: 10.1210/en.2019-00137. pmid: 31415088
[23]	Sucquart IE, Coyle C, Rodriguez Paris V, et al. Investigating GABA Neuron-Specific Androgen Receptor Knockout in two Hyperandrogenic Models of PCOS[J]. Endocrinology, 2024, 165(7):bqae060. doi: 10.1210/endocr/bqae060.
[24]	Childs GV, Odle AK, MacNicol MC, et al. The Importance of Leptin to Reproduction[J]. Endocrinology, 2021, 162(2):bqaa204. doi: 10.1210/endocr/bqaa204.
[25]	Nohara K, Zhang Y, Waraich RS, et al. Early-life exposure to testosterone programs the hypothalamic melanocortin system[J]. Endocrinology, 2011, 152(4):1661-1669. doi: 10.1210/en.2010-1288. pmid: 21303958
[26]	Cara AL, Burger LL, Beekly BG, et al. Deletion of Androgen Receptor in LepRb Cells Improves Estrous Cycles in Prenatally Androgenized Mice[J]. Endocrinology, 2023, 164(3):bqad015. doi: 10.1210/endocr/bqad015.
[27]	Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies[J]. Mol Metab, 2020, 35:100937. doi: 10.1016/j.molmet.2020.01.001.
[28]	Zhu B, Chen Y, Xu F, et al. Androgens impair β-cell function in a mouse model of polycystic ovary syndrome by activating endoplasmic reticulum stress[J]. Endocr Connect, 2021, 10(3):265-272. doi: 10.1530/EC-20-0608. pmid: 33543730
[29]	Yuan C, Huang WQ, Guo JH, et al. Involvement of kisspeptin in androgen-induced hypothalamic endoplasmic reticulum stress and its rescuing effect in PCOS rats[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(12):166242. doi: 10.1016/j.bbadis.2021.166242.